Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$31.33

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $31.33 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $31.33 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1578511283?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $31.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $31.3304/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202019518 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

290 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $26,000.00 12/28/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C. DBA NEBRASKA CANCER SPECIALISTS
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 740785205
Principal investigator 1 Astellas Pharma Global Development $1,358.50 12/23/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) No dispute reported 06/30/2026 721323281
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 12/21/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783605
Principal investigator 1 Exelixis Inc. $6,117.45 12/17/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578701
Principal investigator 1 Exelixis Inc. $6,543.81 12/17/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578717
Principal investigator 1 Exelixis Inc. $20,717.05 12/17/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578833
Principal investigator 1 Merck Sharp & Dohme Corporation $55,338.00 12/16/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma No dispute reported 06/30/2026 740814151
Principal investigator 1 Exelixis Inc. $5,980.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578955
Principal investigator 1 Exelixis Inc. $17,550.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578957
Principal investigator 1 Exelixis Inc. $326.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578959
Principal investigator 1 Exelixis Inc. $260.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578961
Principal investigator 1 Exelixis Inc. $345.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578963
Principal investigator 1 Exelixis Inc. $1,040.00 12/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736578965
Principal investigator 1 Dynavax Technologies Corporation $500.00 12/14/2020 Non-covered Recipient Entity
Oncology Hematology West
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 747905415
Principal investigator 1 Astellas Pharma Global Development $9,721.74 12/10/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) No dispute reported 06/30/2026 721323191
Principal investigator 1 Merck Sharp & Dohme Corporation $69,375.54 12/07/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783615
Principal investigator 1 Merck Sharp & Dohme Corporation $5,475.00 12/04/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730271
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 11/30/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740783519
Principal investigator 1 Merck Sharp & Dohme Corporation $94.00 11/20/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 740730269
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 11/16/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783567
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 11/14/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740783517
Principal investigator 1 Merck Sharp & Dohme Corporation $241.80 11/14/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783561
Principal investigator 1 Astellas Pharma Global Development $3,462.00 11/12/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 721320531
Principal investigator 1 Immunomedics, Inc. $1,250.00 11/10/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
IMMU-132-06 No dispute reported 06/30/2026 750667613
Principal investigator 1 Dynavax Technologies Corporation $25,330.50 11/09/2020 Non-covered Recipient Entity
Oncology Hematology West
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 747905417
Principal investigator 1 Merck Sharp & Dohme Corporation $5.22 11/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730181
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 11/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730273
Principal investigator 1 Merck Sharp & Dohme Corporation $34.35 11/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730275
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730277
Principal investigator 1 Merck Sharp & Dohme Corporation $57,812.95 11/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783613
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $97.43 10/27/2020 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 736761033
Principal investigator 1 Exelixis Inc. $7,063.16 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578115
Principal investigator 1 Exelixis Inc. $3,120.00 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578291
Principal investigator 1 Exelixis Inc. $3,900.00 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578293
Principal investigator 1 Exelixis Inc. $130.00 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578295
Principal investigator 1 Exelixis Inc. $104.00 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578297
Principal investigator 1 Exelixis Inc. $390.00 10/27/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578299
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 10/26/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783565
Principal investigator 1 Astellas Pharma Global Development $3,462.00 10/22/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 721320529
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $500.00 10/21/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
PCYC-1128-CA No dispute reported 06/30/2026 727740109
Principal investigator 1 Merck Sharp & Dohme Corporation $55.80 10/20/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740783609
Principal investigator 1 PFIZER INC. $22,500.00 10/17/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742920195
Principal investigator 1 PFIZER INC. $1,250.00 10/17/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742920197
Principal investigator 1 Merck Sharp & Dohme Corporation $16,425.00 10/16/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730267
Principal investigator 1 Eisai Inc. $899.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112389
Principal investigator 1 Eisai Inc. $450.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112407
Principal investigator 1 Eisai Inc. $565.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112409
Principal investigator 1 Eisai Inc. $899.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112411
Principal investigator 1 Eisai Inc. $450.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112413
Principal investigator 1 Eisai Inc. $565.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112867
Principal investigator 1 Eisai Inc. $956.00 10/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749120795
Principal investigator 1 Incyte Corporation $1,063.00 10/15/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304257
Principal investigator 1 Janssen Research & Development, LLC $547.00 10/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515391
Principal investigator 1 Janssen Research & Development, LLC $145.00 10/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515395
Principal investigator 1 Janssen Research & Development, LLC $547.00 10/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515399
Principal investigator 1 Merck Sharp & Dohme Corporation $209.20 10/15/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740783559
Principal investigator 1 Merck Sharp & Dohme Corporation $484.50 10/15/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783607
Principal investigator 1 Merck Sharp & Dohme Corporation $31,496.40 10/14/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 740730245
Recipient Eli Lilly and Company $705.81 10/08/2020 Covered Recipient Physician A PHASE 1, NONRANDOMIZED, OPEN-LABEL INVESTIGATION OF SUBCUTANEOUS RAMUCIRUMAB ADMINISTRATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 728724565
Principal investigator 1 Merck Sharp & Dohme Corporation $57,812.95 10/06/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740783611
Principal investigator 1 Exelixis Inc. $5,418.92 09/29/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577749
Principal investigator 1 EMD Serono, Inc. $14,750.00 09/24/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-Label, Phase I Dose-Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 749617743
Principal investigator 1 Merck Sharp & Dohme Corporation $100.46 09/23/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 740730241
Principal investigator 1 Eisai Inc. $899.00 09/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112957
Principal investigator 1 Eisai Inc. $450.00 09/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112959
Principal investigator 1 Exelixis Inc. $1,696.17 09/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576963
Principal investigator 1 Exelixis Inc. $14,875.51 09/15/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577319
Principal investigator 1 Janssen Research & Development, LLC $218.00 09/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515094
Principal investigator 1 Merck Sharp & Dohme Corporation $241.80 09/09/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740782965
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 09/07/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705823
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 09/07/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705825
Principal investigator 1 Merck Sharp & Dohme Corporation $241.80 09/07/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740783563
Principal investigator 1 Merck Sharp & Dohme Corporation $57,812.95 08/31/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705871
Principal investigator 1 Exelixis Inc. $195.00 08/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576571
Principal investigator 1 Exelixis Inc. $65.00 08/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576885
Principal investigator 1 Exelixis Inc. $1,950.00 08/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576923
Principal investigator 1 Exelixis Inc. $1,560.00 08/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576941
Principal investigator 1 Exelixis Inc. $2,600.00 08/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577019
Principal investigator 1 Eisai Inc. $899.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112041
Principal investigator 1 Eisai Inc. $450.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112087
Principal investigator 1 Eisai Inc. $565.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112089
Principal investigator 1 Eisai Inc. $899.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112091
Principal investigator 1 Eisai Inc. $450.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112093
Principal investigator 1 Eisai Inc. $565.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112095
Principal investigator 1 Eisai Inc. $899.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112097
Principal investigator 1 Eisai Inc. $450.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112099
Principal investigator 1 Eisai Inc. $899.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112149
Principal investigator 1 Eisai Inc. $450.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112151
Principal investigator 1 Eisai Inc. $565.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112153
Principal investigator 1 Eisai Inc. $565.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112245
Principal investigator 1 Eisai Inc. $899.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112247
Principal investigator 1 Eisai Inc. $450.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112249
Principal investigator 1 Eisai Inc. $565.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112251
Principal investigator 1 Eisai Inc. $520.00 08/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112289
Principal investigator 1 Janssen Research & Development, LLC $393.00 08/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515083
Principal investigator 1 Janssen Research & Development, LLC $218.00 08/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515087
Principal investigator 1 Janssen Research & Development, LLC $145.00 08/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515090
Principal investigator 1 Exelixis Inc. $65.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576443
Principal investigator 1 Exelixis Inc. $3,900.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576467
Principal investigator 1 Exelixis Inc. $1,304.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576513
Principal investigator 1 Exelixis Inc. $750.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576517
Principal investigator 1 Exelixis Inc. $2,990.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576817
Principal investigator 1 Exelixis Inc. $260.00 08/13/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576829
Principal investigator 1 Merck Sharp & Dohme Corporation $13,500.00 08/12/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740814147
Principal investigator 1 Merck Sharp & Dohme Corporation $253.00 08/12/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740814149
Principal investigator 1 Incyte Corporation $32.86 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304217
Principal investigator 1 Incyte Corporation $3.04 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304219
Principal investigator 1 Incyte Corporation $49.29 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304221
Principal investigator 1 Incyte Corporation $5.20 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304223
Principal investigator 1 Incyte Corporation $1.52 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304225
Principal investigator 1 Incyte Corporation $42.75 08/10/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304227
Principal investigator 1 Merck Sharp & Dohme Corporation $972.35 08/07/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740827349
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 08/03/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705419
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 08/03/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740705723
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 07/30/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705919
Principal investigator 1 PFIZER INC. $2,500.00 07/30/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742915883
Principal investigator 1 PFIZER INC. $1,134.41 07/29/2020 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialists
A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF No dispute reported 06/30/2026 742958373
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $157.95 07/28/2020 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase III Adjuvant Melanoma Stage II B C Opdivo Mono No dispute reported 06/30/2026 736761031
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 07/27/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705417
Principal investigator 1 Merck Sharp & Dohme Corporation $93.00 07/24/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705733
Principal investigator 1 Exelixis Inc. $65.00 07/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576301
Principal investigator 1 Exelixis Inc. $163.00 07/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576321
Principal investigator 1 Exelixis Inc. $345.00 07/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576413
Principal investigator 1 Exelixis Inc. $260.00 07/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576561
Principal investigator 1 Exelixis Inc. $3,900.00 07/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736576645
Principal investigator 1 Merck Sharp & Dohme Corporation $57,812.95 07/21/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705869
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 07/17/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740705873
Principal investigator 1 Exelixis Inc. $195.00 07/16/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576273
Principal investigator 1 Exelixis Inc. $1,950.00 07/16/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576331
Principal investigator 1 Exelixis Inc. $65.00 07/16/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576351
Principal investigator 1 Exelixis Inc. $1,560.00 07/16/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576823
Principal investigator 1 Eisai Inc. $956.00 07/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112003
Principal investigator 1 Incyte Corporation $1,063.00 07/15/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304205
Principal investigator 1 Janssen Research & Development, LLC $218.00 07/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515063
Principal investigator 1 Janssen Research & Development, LLC $393.00 07/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515067
Principal investigator 1 Janssen Research & Development, LLC $393.00 07/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515071
Principal investigator 1 Janssen Research & Development, LLC $145.00 07/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515075
Principal investigator 1 Janssen Research & Development, LLC $547.00 07/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515079
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $2,000.00 07/09/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 736764659
Principal investigator 1 Exelixis Inc. $2,600.00 07/07/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576269
Principal investigator 1 Exelixis Inc. $7,800.00 07/07/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576327
Principal investigator 1 Exelixis Inc. $65.00 07/07/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576347
Principal investigator 1 Exelixis Inc. $390.00 07/07/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576451
Principal investigator 1 ARRAY BIOPHARMA INC $850.00 07/02/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742875755
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,857.00 07/01/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 736764395
Principal investigator 1 Merck Sharp & Dohme Corporation $10,950.00 06/26/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730239
Principal investigator 1 ARRAY BIOPHARMA INC $1,075.00 06/23/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742878523
Principal investigator 1 Exelixis Inc. $4,953.80 06/23/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736575949
Principal investigator 1 Astellas Pharma Global Development $6,924.00 06/16/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 721320527
Principal investigator 1 Exelixis Inc. $1,950.00 06/16/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736575951
Principal investigator 1 Merck Sharp & Dohme Corporation $57,812.95 06/16/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705867
Principal investigator 1 Eisai Inc. $520.00 06/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111841
Principal investigator 1 Eisai Inc. $580.00 06/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111843
Principal investigator 1 Eisai Inc. $580.00 06/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112083
Principal investigator 1 Janssen Research & Development, LLC $393.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515143
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515146
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515149
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515153
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515157
Principal investigator 1 Janssen Research & Development, LLC $145.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515161
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515165
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515169
Principal investigator 1 Janssen Research & Development, LLC $393.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515173
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515177
Principal investigator 1 Janssen Research & Development, LLC $145.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515183
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515185
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515189
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515193
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515197
Principal investigator 1 Janssen Research & Development, LLC $145.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515201
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515205
Principal investigator 1 Janssen Research & Development, LLC $145.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515209
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515213
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515217
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515223
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515225
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515230
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515235
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515239
Principal investigator 1 Janssen Research & Development, LLC $393.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515243
Principal investigator 1 Janssen Research & Development, LLC $145.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515247
Principal investigator 1 Janssen Research & Development, LLC $393.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515251
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515255
Principal investigator 1 Janssen Research & Development, LLC $547.00 06/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515259
Principal investigator 1 Merck Sharp & Dohme Corporation $115.05 06/15/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705411
Principal investigator 1 Merck Sharp & Dohme Corporation $32,569.95 06/15/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705781
Principal investigator 1 Merck Sharp & Dohme Corporation $644.85 06/08/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705777
Principal investigator 1 Merck Sharp & Dohme Corporation $5,475.00 06/08/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730237
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $272.70 06/01/2020 Non-covered Recipient Entity
Us Oncology Reserch Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 713687779
Principal investigator 1 Merck Sharp & Dohme Corporation $130.20 05/28/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 740705413
Principal investigator 1 Merck Sharp & Dohme Corporation $578.70 05/28/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740705729
Principal investigator 1 Merck Sharp & Dohme Corporation $910.05 05/28/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705731
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $500.00 05/28/2020 Non-covered Recipient Entity
Clearview Cancer Institute-Hunstville ( Main)
PCYC-1128-CA No dispute reported 06/30/2026 727731945
Principal investigator 1 Merck Sharp & Dohme Corporation $46,250.36 05/26/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705829
Principal investigator 1 Merck Sharp & Dohme Corporation $21,600.00 05/20/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies No dispute reported 06/30/2026 740827347
Principal investigator 1 ARRAY BIOPHARMA INC $625.00 05/19/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742877865
Principal investigator 1 ARRAY BIOPHARMA INC $900.00 05/19/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742877929
Principal investigator 1 ARRAY BIOPHARMA INC $775.00 05/19/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742878441
Principal investigator 1 ARRAY BIOPHARMA INC $1,225.00 05/19/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742878525
Principal investigator 1 ARRAY BIOPHARMA INC $1,750.00 05/19/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742878589
Principal investigator 1 Merck Sharp & Dohme Corporation $488.00 05/19/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740705727
Principal investigator 1 PFIZER INC. $1,250.00 05/19/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742915887
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,300.00 05/18/2020 Non-covered Recipient Entity
Us Oncology Res Llc
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 736764279
Principal investigator 1 Bausch Health US, LLC $12,500.00 05/08/2020 Non-covered Recipient Individual PHASE 2 PANCREATIC CT No dispute reported 06/30/2026 737374227
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 04/30/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 740705915
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 04/30/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705917
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 04/27/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 740705819
Principal investigator 1 Astellas Pharma Global Development $2,250.37 04/23/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) No dispute reported 06/30/2026 721321763
Principal investigator 1 Astellas Pharma Global Development $13,000.00 04/23/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) No dispute reported 06/30/2026 721321765
Principal investigator 1 Merck Sharp & Dohme Corporation $1,920.60 04/17/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 740730213
Principal investigator 1 Merck Sharp & Dohme Corporation $5,475.00 04/17/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730235
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,469.00 04/16/2020 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 736764345
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,805.00 04/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 736761497
Principal investigator 1 Eisai Inc. $450.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110673
Principal investigator 1 Eisai Inc. $565.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110727
Principal investigator 1 Eisai Inc. $956.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111065
Principal investigator 1 Eisai Inc. $520.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111247
Principal investigator 1 Eisai Inc. $565.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112219
Principal investigator 1 Eisai Inc. $899.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112221
Principal investigator 1 Eisai Inc. $450.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112223
Principal investigator 1 Eisai Inc. $565.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749112225
Principal investigator 1 Eisai Inc. $899.00 04/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749120963
Principal investigator 1 Incyte Corporation $1,063.00 04/15/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744304187
Principal investigator 1 Merck Sharp & Dohme Corporation $46,250.36 04/13/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705827
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 04/13/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705877
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $7,265.00 04/07/2020 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
PCYC-1128-CA No dispute reported 06/30/2026 727731991
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 03/23/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 740705415
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 03/23/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705725
Principal investigator 1 Merck Sharp & Dohme Corporation $10,950.00 03/18/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730207
Principal investigator 1 PFIZER INC. $49,257.76 03/17/2020 Non-covered Recipient Entity
Nebraska Cancer Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES No dispute reported 06/30/2026 742915437
Principal investigator 1 Eisai Inc. $565.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110649
Principal investigator 1 Eisai Inc. $450.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110651
Principal investigator 1 Eisai Inc. $565.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110653
Principal investigator 1 Eisai Inc. $899.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110655
Principal investigator 1 Eisai Inc. $450.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110771
Principal investigator 1 Eisai Inc. $899.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110817
Principal investigator 1 Eisai Inc. $565.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110819
Principal investigator 1 Eisai Inc. $899.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110821
Principal investigator 1 Eisai Inc. $450.00 03/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110823
Principal investigator 1 Janssen Research & Development, LLC $6,375.00 03/15/2020 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 719515305
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $273.38 03/10/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 736761507
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,846.00 03/06/2020 Non-covered Recipient Entity
Us Oncology Res Llc
Phase IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 736764125
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $4,000.00 03/05/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 736764569
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 03/03/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705923
Principal investigator 1 Merck Sharp & Dohme Corporation $46,246.88 03/03/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705963
Principal investigator 1 Astellas Pharma Global Development $2,052.70 03/02/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY TO EVALUATE ENFORTUMAB VEDOTIN VS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (EV-301) No dispute reported 06/30/2026 721321303
Principal investigator 1 PFIZER INC. $15,000.00 02/28/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742966434
Principal investigator 1 PFIZER INC. $3,500.00 02/28/2020 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 742966447
Principal investigator 1 ARRAY BIOPHARMA INC $625.00 02/25/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742877861
Principal investigator 1 Merck Sharp & Dohme Corporation $154.80 02/24/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730211
Principal investigator 1 ARRAY BIOPHARMA INC $2,425.00 02/20/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742875611
Principal investigator 1 ARRAY BIOPHARMA INC $750.00 02/20/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742875613
Principal investigator 1 ARRAY BIOPHARMA INC $775.00 02/20/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742875757
Principal investigator 1 ARRAY BIOPHARMA INC $500.00 02/20/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742877869
Principal investigator 1 ARRAY BIOPHARMA INC $750.00 02/20/2020 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742878585
Principal investigator 1 Exelixis Inc. $1,500.25 02/20/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736574957
Principal investigator 1 Merck Sharp & Dohme Corporation $5,426.24 02/19/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 740730243
Principal investigator 1 Exelixis Inc. $14,030.95 02/11/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 736574959
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,000.00 02/05/2020 Non-covered Recipient Entity
Hematology / Oncology West Pc
Phase III Adjuvant Melanoma Stage II B C Opdivo Mono No dispute reported 06/30/2026 736760159
Principal investigator 1 Janssen Research & Development, LLC $1,592.00 02/05/2020 Non-covered Recipient Entity
Nebraska Methodist Hosp Diabetes
An Open Label Phase 1-2 Safety Pharmacokinetic and Proof of Concept Study of ARN 509 in patients with Progressive metastatic Castration Resistant prostate Cancer No dispute reported 06/30/2026 719509247
Principal investigator 1 PFIZER INC. $13,400.00 01/29/2020 Non-covered Recipient Entity
Oncology Hematology West PC dba Nebraska Cancer Specialist
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES No dispute reported 06/30/2026 742966133
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $450.00 01/28/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study No dispute reported 06/30/2026 736761505
Principal investigator 1 Merck Sharp & Dohme Corporation $177.75 01/24/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 740705779
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,408.00 01/22/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab No dispute reported 06/30/2026 736764733
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 01/22/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705921
Principal investigator 1 Merck Sharp & Dohme Corporation $46,246.88 01/22/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705925
Principal investigator 1 Merck Sharp & Dohme Corporation $1,131.20 01/22/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 740730209
Principal investigator 1 AstraZeneca AB $217,655.68 01/21/2020 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer No dispute reported 06/30/2026 736743185
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,550.00 01/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
SUSTAIN, event driven trial No dispute reported 06/30/2026 736761491
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,740.00 01/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Phase IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 736761493
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,156.00 01/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Nivo RCC Safety Trial No dispute reported 06/30/2026 736761499
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,376.03 01/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Nivo Dose Frequency Optimization Lung Trial No dispute reported 06/30/2026 736761501
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,694.00 01/15/2020 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 736761503
Principal investigator 1 Eisai Inc. $956.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110413
Principal investigator 1 Eisai Inc. $899.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110479
Principal investigator 1 Eisai Inc. $450.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110483
Principal investigator 1 Eisai Inc. $565.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110499
Principal investigator 1 Eisai Inc. $899.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110511
Principal investigator 1 Eisai Inc. $450.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749110513
Principal investigator 1 Eisai Inc. $1,200.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111227
Principal investigator 1 Eisai Inc. $1,200.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111253
Principal investigator 1 Eisai Inc. $980.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 749111255
Principal investigator 1 Incyte Corporation $1,063.00 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C. DBA NEBRASKA CANCER SPECIALISTS
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 744312793
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.52 01/15/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETINIB VERSUS PLACEBO DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA No dispute reported 06/30/2026 721493821
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,471.52 01/15/2020 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 721494133
Principal investigator 1 Merck Sharp & Dohme Corporation $177.75 01/14/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705771
Principal investigator 1 Exelixis Inc. $1,742.58 01/09/2020 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574671
Principal investigator 1 Merck Sharp & Dohme Corporation $832.10 01/08/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 740705775
Principal investigator 1 Merck Sharp & Dohme Corporation $262.70 01/06/2020 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 No dispute reported 06/30/2026 740705773
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,147.00 01/02/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 736764427